Richard L Darley
Overview
Explore the profile of Richard L Darley including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
491
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Rastogi N, Gonzalez J, Srivastava V, Alanazi B, Alanazi R, Hughes O, et al.
Leukemia
. 2022 Dec;
37(2):276-287.
PMID: 36572750
Nuclear factor I-C (NFIC) belongs to a family of NFI transcription factors that binds to DNA through CAATT-boxes and are involved in cellular differentiation and stem cell maintenance. Here we...
2.
Nicholson R, Menezes A, Azevedo A, Leckenby A, Davies S, Seedhouse C, et al.
Front Oncol
. 2022 Jun;
12:840046.
PMID: 35707351
The protein kinase C (PKC) family of serine/threonine kinases are pleiotropic signaling regulators and are implicated in hematopoietic signaling and development. Only one isoform however, PKCϵ, has oncogenic properties in...
3.
Menezes A, Jones R, Shrestha A, Nicholson R, Leckenby A, Azevedo A, et al.
Leukemia
. 2022 Apr;
36(7):1769-1780.
PMID: 35490198
RUNX3 is a transcription factor dysregulated in acute myeloid leukemia (AML). However, its role in normal myeloid development and leukemia is poorly understood. Here we investigate RUNX3 expression in both...
4.
Wagstaff M, Tsaponina O, Caalim G, Greenfield H, Milton-Harris L, Mancini E, et al.
Haematologica
. 2022 Apr;
108(1):283-289.
PMID: 35443562
No abstract available.
5.
Menezes A, Dixon C, Scholz A, Nicholson R, Leckenby A, Azevedo A, et al.
Sci Rep
. 2022 Jan;
12(1):1243.
PMID: 35075235
RUNX proteins belong to a family of transcription factors essential for cellular proliferation, differentiation, and apoptosis with emerging data implicating RUNX3 in haematopoiesis and haematological malignancies. Here we show that...
6.
Robinson A, Darley R, Tonks A
Oncotarget
. 2021 May;
12(10):952-954.
PMID: 34012508
No abstract available.
7.
Robinson A, Davies S, Darley R, Tonks A
Front Oncol
. 2021 Mar;
11:632623.
PMID: 33777786
Acute myeloid leukemia (AML) is a heterogeneous disease with poor clinical outcomes. We have previously shown that constitutive activation of NADPH oxidase 2 (NOX2), resulting in over-production of reactive oxygen...
8.
Rastogi N, Baker S, Man S, Uger R, Wong M, Coles S, et al.
Br J Haematol
. 2020 Sep;
193(1):155-159.
PMID: 32996123
Treatment of relapsed/resistant acute myeloid leukaemia (AML) remains a significant area of unmet patient need, the outlook for most patients remaining extremely poor. A promising approach is to augment the...
9.
Robinson A, Hopkins G, Rastogi N, Hodges M, Doyle M, Davies S, et al.
Cancer Res
. 2019 Dec;
80(5):937-949.
PMID: 31862780
Acute myeloid leukemia (AML) is a heterogeneous clonal disorder with a poor clinical outcome. Previously, we showed that overproduction of reactive oxygen species (ROS), arising from constitutive activation of NOX2...
10.
Alanazi B, Munje C, Rastogi N, Williamson A, Taylor S, Hole P, et al.
Leukemia
. 2019 Oct;
34(2):427-440.
PMID: 31611628
Inappropriate localization of proteins can interfere with normal cellular function and drive tumor development. To understand how this contributes to the development of acute myeloid leukemia (AML), we compared the...